Innovative Swedish biotech organisation Neogap Therapeutics has recruited bioinformatics and software development expert Alejandro Fernandez Woodbridge to further strengthen the development of its software platform, PIOR®, for personalised cancer immunotherapy.
What does Alejandro bring to Neogap in the role?
Alejandro Fernandez Woodbridge holds a PhD in bioinformatics of 3D chromatin architecture and epigenetics from Karolinska Institutet and has extensive experience in transcriptomics and proteomics from his postdoc at SciLife lab. Prior to joining Neogap, Alejandro co-founded two successful consultancy companies specialising in bioinformatics and machine learning.
Commenting on the appointment, Samuel Svensson, CEO of Neogap, said, “We are delighted to welcome Alejandro Fernandez Woodbridge to our team. With over two decades of experience in bioinformatics and software development, his distinguished background will be invaluable for further development of PIOR® in the field of cell therapy and diagnostics.”
Neogap’s PIOR® software platform plays a crucial role in the company’s immunotherapy program, enabling the identification, selection, and ranking of tumour-specific T-lymphocyte targets (neoantigen peptides) for personalised T-lymphocyte therapy. The platform, PIOR®, leverages machine learning to capture improvements in neoantigen prediction and next-generation sequencing. It is also compliant with GDPR and other industry quality standards.
